Viemed (VMD) Q1 2026 Earnings Transcript

Viemed Healthcare reported Q1 revenue of $75.4 million, up 28% year over year, with adjusted EBITDA of $14.3 million and free cash flow turning positive at $2.6 million versus negative $5.7 million last year. Management raised the low end of 2026 net revenue guidance to $312 million-$320 million, reaffirmed $65 million-$69 million adjusted EBITDA, and cut net CapEx guidance to 9%-10.5% of revenue. The business also showed continued mix diversification, with sleep patients up 57%, maternal health scaling into new markets, and ventilator revenue falling to 47% of sales from 54% a year ago.

Analysis

VMD is transitioning from a levered reimbursement story into a capital-efficient recurring revenue compounder. The key second-order effect is that mix shift away from ventilators toward sleep resupply and maternal health reduces capital intensity, payer concentration, and earnings volatility simultaneously, which should support a re-rating if investors start valuing the business on free cash flow rather than revenue multiple. The positive FCF inflection is more important than headline growth because it creates optionality: buybacks, debt paydown, and M&A can all now be funded without stressing the balance sheet.

The market may still be underestimating how much of the growth is self-reinforcing. Bigger PAP installed base feeds resupply; resupply improves cash generation; stronger cash flow funds more market expansion and back-office automation; that in turn lowers SG&A as a percent of revenue. The maternal platform appears to be the most underappreciated lever because it scales through existing payer and fulfillment infrastructure, meaning incremental revenue should arrive with better unit economics than the core business.

Main risk is not demand collapse but execution friction in the NCD transition. Higher compliance standards can create short-term churn and make the ventilator census look worse before it looks better; that can mask underlying setup momentum and create a window where the stock de-rates on reported patient counts. The more immediate catalyst path is a couple of quarters of sequential 3%-5% growth plus continued FCF expansion, which would force the street to update margin and terminal value assumptions. If management can keep CapEx below guidance and sustain buybacks, the stock likely has room to rerate before revenue growth alone is fully visible.

Key Decisions for Investors

• Go long VMD on pullbacks over the next 2-4 weeks; target a 6-12 month hold. Risk/reward improves if the market continues to anchor on ventilator census rather than trailing FCF. Base case is a multiple expansion as FCF and buybacks become the dominant narrative.
• Pair trade: long VMD / short a basket of higher-quality but slower-growth DME reimbursement names over 3-6 months. Thesis: VMD has a cleaner path to FCF inflection and mix diversification, while peers remain more exposed to payer/regulatory drag.
• Use call spreads in VMD for the next 2-3 quarters rather than common if you want convexity into the sequential revenue ramp. Upside catalyst is another guide raise or evidence that maternal health can scale without proportional SG&A growth.
• If already long, hedge near-term volatility with a tight trailing stop tied to ventilator compliance headlines over the next 1-2 quarters. The main downside scenario is reporting noise from NCD-driven churn causing investors to miss underlying operating leverage.
• Consider adding on any post-earnings weakness if free cash flow remains positive and CapEx guidance stays below prior range. That would confirm the market is still mispricing the shift from capital consumption to capital return.